-
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will…
-
Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie
Bensheim, 23.01.2024 – Erste Studien zeigen, dass neuropathische Schmerzformen, wie CINP, eine vielversprechende Indikation für den Nutzen von CBMs darstellen könnten. Jedoch fehlt – wie so oft in der Cannabis Medizin – eine belastbare Evidenz für diese sensible Patientengruppe. Die Deutsche Gesellschaft für Schmerzmedizin e.V. (DGS) und der forschungsorientierte Hersteller von Cannabis-basierten Arzneimitteln Avextra adressieren…
-
Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.
Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten klinischen Studie für Onkologiepatient:innen
-
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich from September 14 to 17, 2022…
-
Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie
Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra name.
-
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich from September 14 to 17, 2022…
-
Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.
Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra name.
-
Avextra AG Announces Closing of EU 17 Million Capital Raise
Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich from September 14 to 17, 2022…
-
Avextra erweitert Cannabis-Portfolio um neue Dronabinol-Lösung
Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich from September 14 to 17, 2022…
-
Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom
Bensheim, Gemünden (Wohra) and Gauting, 09. November 2022 – Together these three partners will develop a pathway for the first cannabis inhalers to comply with European Medical Device Regulations…
